The first breakthrough approach was imatinib for the treatment of patients affected by chronic myeloid leukemia (CML) (3) because the rational development of the drug was guided by the recognition of the BCR-Abl fusion protein as the primary cause of leukemia. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.